Investors seeking early exposure to emerging life sciences companies will have a direct line to management teams on September 17, 2026, when the Life Sciences Virtual Investor Forum convenes online. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the event features 30-minute live presentations and audience Q&A sessions from seven companies whose pipelines target some of medicine’s most challenging areas. The forum’s lineup spans photothermal cancer therapy, cannabinoid-based formulations, precision drug delivery, a new class of antibiotics, a humanized monoclonal antibody, Focal Adhesion Kinase inhibitors, and FDA-cleared four-dimensional respiratory imaging.
The implications for investors are significant. Unlike static filings, the live format allows shareholders and potential investors to hear directly from executives and probe them with impromptu questions. As David Shapiro, Chief Executive Officer of B2i Digital, Inc., noted, “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” This real-time engagement can reveal management’s confidence, strategic priorities, and responsiveness—factors that often influence investment decisions.
The presenting companies, as of September 11, 2026, include Sona Nanotech Inc. at 11:00 AM ET, Raphael Pharmaceutical at 11:30 AM ET, Amplia Therapeutics Ltd. at 2:00 PM ET, Adaptin Bio, Inc. at 2:30 PM ET, Acurx Pharmaceuticals, Inc. at 3:00 PM ET, CytoDyn Inc. at 3:30 PM ET, and 4DMedical Ltd. at 4:00 PM ET. Each brings a distinct approach: Sona Nanotech’s photothermal cancer therapy built on gold nanorods; Raphael Pharmaceutical’s cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease; Adaptin Bio’s precision drug delivery aimed at tissues including behind the blood-brain barrier; Acurx Pharmaceuticals’ new class of antibiotics for infections caused by priority pathogens; CytoDyn’s humanized monoclonal antibody in solid-tumor oncology; Amplia Therapeutics’ pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis; and 4DMedical’s FDA-cleared four-dimensional respiratory imaging.
For investors, the forum offers a rare opportunity to compare diverse therapeutic approaches in one sitting and assess near-term catalysts. The antibiotic space, for instance, has seen limited innovation despite rising antimicrobial resistance, making Acurx’s progress noteworthy. Similarly, cannabinoid-based therapies for autoimmune conditions could open new treatment avenues if clinical results support them. The event also underscores the global nature of life sciences investing, with companies listed on exchanges including ASX, OTC Markets, and Nasdaq.
Registration is available at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC, and event details with presenting company profiles are at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. Replays will be available on the B2i Digital and OTC Markets YouTube channels. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features public companies from exchanges worldwide, providing efficient access to a broad investor audience through live presentations, Q&A, and one-on-one meetings.
